We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current TRVI market cap is 177.52M. The company's latest EPS is USD -0.4552 and P/E is -6.06.
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -8.41M | -6.66M | -7.56M | -8.38M | -9.05M |
| Net Income | -8.27M | -5.51M | -6.4M | -7.15M | -7.7M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -26.65M | -32.49M | -32.48M | -29.91M | -33.92M |
| Net Income | -25.22M | -32.76M | -33.94M | -29.15M | -29.07M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 128.36M | 123.02M | 116.21M | 100.98M | 95.9M |
| Total Liabilities | 18.46M | 15.56M | 14.47M | 5.9M | 6.29M |
| Total Equity | 109.9M | 107.46M | 101.73M | 95.07M | 89.61M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 60M | 47.13M | 38.48M | 123.02M | 89.4M |
| Total Liabilities | 5.46M | 19.85M | 21.4M | 15.56M | 6.86M |
| Total Equity | 54.55M | 27.28M | 17.08M | 107.46M | 82.55M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -21.84M | -28.18M | -8.2M | -18.07M | -25.35M |
| Investing | -59.07M | -107.37M | 8.96M | 28.6M | 46.58M |
| Financing | 110.66M | 111.31M | -1.7M | -9.37M | -7.86M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -23.09M | -29M | -28.95M | -28.18M | -31.71M |
| Investing | -9k | -32k | N/A | -107.37M | 59.43M |
| Financing | 73.21M | 16.72M | 20.78M | 111.31M | -7.91M |
| Market Cap | 177.52M |
| Price to Earnings Ratio | -6.06 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 5.44 |
| Price to Book Ratio | 2.14 |
| Dividend Yield | - |
| Shares Outstanding | 63.86M |
| Average Volume (1 week) | 163.33k |
| Average Volume (1 Month) | 268.39k |
| 52 Week Change | -7.64% |
| 52 Week High | 4.00 |
| 52 Week Low | 0.97 |
| Spread (Intraday) | 1.16 (29.82%) |
| Company Name | Trevi Therapeutics Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.trevitherapeutics.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
